Ascletis Pharma Inc.
1672
株式のランク
#10492
Ascletis Pharma Inc., a biotechnology company, engages in the research and... Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.
株価
$0.74836845
最終同期: 2026-10-16
時価総額
$785.53M
変化（1日）
1.12%
変化（1年）
-38.66%
国
CN
取引 Ascletis Pharma Inc. (1672)
カテゴリー
Healthcare
の時価総額 Ascletis Pharma Inc.(1672)
時価総額: $785.53M
October 2026時点で、Ascletis Pharma Inc. の時価総額は $785.53M です。これは、当社のデータによると、Ascletis Pharma Inc. が世界で10492nd番目に価値のある企業であることを意味します。時価総額は、上場企業の発行済株式の総市場価値であり、企業の価値を測るためによく使用されます。
Ascletis Pharma Inc. の時価総額の履歴（2019 から 2026 まで）
